Drug-class segmentation of the cancer pain
The international survey showed that more than half of the world's population live in countries where regulations aiming to stem drug misuse leave patients without access to opioid medicines for managing cancer pain
Breakthrough pain ("BTP") is an acute and often severe flare of pain experienced by patients treated with round the clock opioid analgesics for their underlying chronic cancer pain
The World Health Organization has previously said that the mainstay of cancer pain
relief should be opioids (narcotics)," says AHCPR panel member Dr.
The report also finds that one of the greatest commercial opportunities in cancer pain
is for effective products that lack the gastrointestinal and central nervous system side effects of opioid analgesics.
The survey shows that distinguishing a patient's breakthrough cancer pain
as a separate symptom from their chronic background pain represents an area of challenge for nurses practicing in a cancer setting.
Our partnership with NewBridge will allow Abstral to be available for thousand of doctors to help them manage patients suffering breakthrough cancer pain
,' Bjerke added
Breakthrough cancer pain
is a brief and often severe flare of pain experienced by patients suffering from cancer that occurs even though a person may be taking pain relief medicine regularly for their persistent pain.
I certainly enjoyed reading this book and would highly recommend it to all involved in cancer pain
Our studies have shown that the majority of physicians are willing to prescribe adequate drugs to manage cancer pain
Looking at cancer pain
[in adults], the rule of thumb is that psychological factors have been overinvoked as reasons why people have pain," Cleeland says.
It also reviews key players involved in the therapeutic development for Cancer Pain
GlobalData's clinical trial report, "Cancer Pain
Global Clinical Trials Review, H1, 2013" provides data on the Cancer Pain
clinical trial scenario.
BRUSSELS, October 7, 2010 /PRNewswire/ -- The European Oncology Nursing Society (EONS) launches first European nurse initiative to examine current practices in Breakthrough Cancer Pain
and look at ways of improving patient outcomes in palliative care
Archimedes Pharma Ltd ("Archimedes"), a European specialty pharmaceutical company, today announces the commencement of its global Phase III programme for Nasalfent(r) in breakthrough cancer pain